Reactive cutaneous capillary endothelial proliferation caused by camrelizumab: Sixteen case reports

Indian Journal of Dermatology 2023 68(3):318-326 To investigate the regularity and characteristics of adverse drug reaction (ADR) of reactive cutaneous capillary endothelial proliferation caused by Camrelizumab, so as to provide reference for clinical rational use of drugs. Searching for case reports of Camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP) in databases such as China Biology Medicine disc, VIP Database, CNKI, Wanfang Medical, PubMed, Wiley online library, Embase with “Carritzumab/Ericab,” “SHR-1210,” “Reactive cutaneous capillary endothelial proliferation,” “Reactive capillary hemangiomas,” and “Capillary proliferation” as search terms. The retrieval time is from the establishment of the database to February 2022. After eliminating clinical trials and incomplete literature, information of patients included in the literature was analyzed, which included gender, age, reason for medication, usage and dosage, time of ADR, concomitant medication, clinical manifestations, intervention measures, outcomes of patients, etc. A total of 11 articles involving 16 patients were included, including 11 males and five females, with an average age of 60.5 years. Reasons for medication included nine cases of non-small cell lung cancer (NSCLC), four cases of liver cancer, one case of small cell lung cancer (SCLC), one cas...
Source: Indian Journal of Dermatology - Category: Dermatology Source Type: research